Understand the source comparison
VIP FDA Approved Status: Research Peptides vs Clinical Therapeutics
| Attribute | Research-Grade VIP Peptide | FDA-Approved Drug ||—|—|—|—|—|—|| Regulatory Pathway | Manufactured under GMP or ISO 9001; no FDA premarket approval required | Requires Phase I–III clinical trials, New Drug Application (NDA), and FDA approval || Pur
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Attribute | Research-Grade VIP Peptide | FDA-Approved Drug ||—|—|—|—|—|—|| Regulatory Pathway | Manufactured under GMP or ISO 9001; no FDA premarket approval required | Requires Phase I–III clinical trials, New Drug Application (NDA), and FDA approval || Purity Verification | HPLC ≥95%, mass spectrometry, LAL endotoxin testing | USP monograph standards, batch-by-batch FDA oversight || Permissible Use | Laboratory research only (in vitro, in vivo animal models) | Human prescription use under physician supervision || Marketing Claims | Molecular descriptors only; no therapeutic claims allowed | Approved indication(s) stated in FDA-approved labeling || Distribution Channels | Research institutions, accredited laboratories | Pharmacies, hospitals, licensed prescribers || Bottom Line | VIP peptides serve as investigational tools. Regulatory compliance centers on manufacturing quality, not clinical efficacy | FDA-approved drugs undergo years of safety and efficacy testing before reaching p